Feb 11, 2025 | News, White Papers
Please click the below link to view our most recent white paper that details the FDA’s guidance on nitrosamines/genotoxic impurities and how ChemWerth has developed a procedure to prevent our products from containing them. Nitrosamines and Genotoxic...
Feb 11, 2025 | News, White Papers
Please click the below link to view our most recent white paper explaining The ChemWerth Advantage and how we are able to get products to market at an unmmatched pace. The ChemWerth Advantage
Feb 7, 2023 | White Papers
Exploring how inadequate U.S. FDA Type II Drug Master Files are one of the leading causes of delayed ANDA approvals.
Feb 7, 2023 | White Papers
Recent, unexpected findings of nitrosamine impurities in drugs such as angiotensin II receptor blockers, ranitidine, nizatidine and metformin have raised RED FLAGS at the FDA.
